BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18559624)

  • 21. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.
    Hong Y; Miao X; Zhang X; Ding F; Luo A; Guo Y; Tan W; Liu Z; Lin D
    Cancer Res; 2005 Oct; 65(20):9582-7. PubMed ID: 16230424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
    Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
    Cescon DW; Bradbury PA; Asomaning K; Hopkins J; Zhai R; Zhou W; Wang Z; Kulke M; Su L; Ma C; Xu W; Marshall AL; Heist RS; Wain JC; Lynch TJ; Christiani DC; Liu G
    Clin Cancer Res; 2009 May; 15(9):3103-9. PubMed ID: 19383811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women.
    Kang S; Wang DJ; Li WS; Wang N; Zhou RM; Sun DL; Duan YN; Li SZ; Li XF; Li Y
    Int J Gynecol Cancer; 2009 May; 19(4):572-7. PubMed ID: 19509552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
    Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 T309G polymorphism is associated with bladder cancer.
    Onat OE; Tez M; Ozçelik T; Törüner GA
    Anticancer Res; 2006; 26(5A):3473-5. PubMed ID: 17094469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRM polymorphisms, pancreatic cancer risk and survival.
    Segedi M; Anderson LN; Espin-Garcia O; Borgida A; Bianco T; Cheng D; Chen Z; Patel D; Brown MC; Xu W; Reisman D; Gallinger S; Cotterchio M; Hung R; Liu G; Cleary SP
    Int J Cancer; 2016 Dec; 139(11):2474-81. PubMed ID: 27487558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
    Chen J; Li D; Killary AM; Sen S; Amos CI; Evans DB; Abbruzzese JL; Frazier ML
    Ann Surg Oncol; 2009 Feb; 16(2):431-9. PubMed ID: 19020940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients.
    Cho YG; Choi BJ; Song JH; Kim CJ; Cao Z; Nam SW; Lee JY; Park WS
    Neoplasma; 2008; 55(3):256-60. PubMed ID: 18348658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
    Maruei-Milan R; Heidari Z; Salimi S
    J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDM2 SNP309 is associated with endometrial cancer risk.
    Terry K; McGrath M; Lee IM; Buring J; De Vivo I
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):983-6. PubMed ID: 18398041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer.
    Jiao L; Bondy ML; Hassan MM; Chang DZ; Abbruzzese JL; Evans DB; Smolensky MH; Li D
    Cancer; 2007 Mar; 109(5):840-8. PubMed ID: 17265526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
    Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome.
    Sotamaa K; Liyanarachchi S; Mecklin JP; Järvinen H; Aaltonen LA; Peltomäki P; de la Chapelle A
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6840-4. PubMed ID: 16203772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma.
    Hermanova M; Karasek P; Nenutil R; Kyr M; Tomasek J; Baltasova I; Dite P
    Pancreas; 2009 Jul; 38(5):565-71. PubMed ID: 19346994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.
    Li D; Jiao L; Li Y; Doll MA; Hein DW; Bondy ML; Evans DB; Wolff RA; Lenzi R; Pisters PW; Abbruzzese JL; Hassan MM
    Carcinogenesis; 2006 Jan; 27(1):103-11. PubMed ID: 15987714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
    Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
    Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.